drugset / Trial / NCT00005090
S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease
Phase 3
Terminated
11 enrolled
SWOG Cancer Research Network
Cancer and Leukemia Group B · collabEastern Cooperative Oncology Group · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known if combination chemotherapy is more effective with or without peripheral stem cell transplantation in treating Hodgkin's Disease. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without peripheral stem cell transplantation in treating men who have stage III or stage IV Hodgkin's disease.
Timeline
- Start
- 2000-04
- Primary completion
- 2005-05
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bleomycin | Unknown | 10 unknown | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 100 mg/kg | Intravenous |
| Subject | Dacarbazine | Small molecule | 375 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 60 mg/kg | Intravenous |
| Subject | Vinblastine | Small molecule | 6 mg/m2 | Intravenous |
| Subject | carmustine | Small molecule | 150 unknown | Intravenous |